DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/14021
Title: Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis
Authors: Chen, Xingchi
Wang, Sainan
Lin, Lulu
Li, Yu
Zhang, Hui
Keywords: Atorvastatin
statins drugs
anti-inflammatory mechanisms
atherosclerotsis
high resolution NMR.
Issue Date: 20-May-2018
Publisher: Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi.
Citation: Chen, X., Wang, S., Lin, L., Li, Y., & Zhang, H. (2018). Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis. Pak J Pharm Sci, 31(3), 1169-73.
Abstract: Atherosclerosis (AS) is a chronic inflammatory reaction with the pathological changes in the lipid deposition of arterial intima. The disorder of blood lipid metabolism is the main factor of the occurrence and development of AS, and the inflammatory reaction and autoimmune reaction also run through the development of AS. In this study, we compared the efficacy and safety of atorvastatin, simvastatin, pravastatin and rosuvastatin in the treatment of AS. At the same time, we used high resolution magnetic resonance imaging (MRI) to assess the changes in plaque area in the middle cerebral artery and the patch area before and after drug treatment. After 6 months of treatment, the number of intima-media thickness (IMT), plaque and plaque in each group were significantly lower than that before the same group. The results showed that statin treatment of AS could significantly reduce the level of blood lipids, but rosuvastatin and atorvastatin had better effects on anti inflammation and maintaining plaque stability and the drug safety was good.
URI: http://142.54.178.187:9060/xmlui/handle/123456789/14021
ISSN: 1011-601X
Appears in Collections:Issues No. 3 (Special)

Files in This Item:
File Description SizeFormat 
15-SP-6293.htm193 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.